Lilly Asia Ventures
Yu Cao, Ph.D., is a Senior Investment Manager with Lilly Asia Ventures (LAV). Prior to joining LAV, Yu was a senior manager of strategic investment and M&A at Microport Scientifc Corporation. Prior to that, Yu served as the Strategy & BD consultant at Saint-Gobain Group. Yu holds a doctoral degree of Engineering from Ecole Centrale Paris in France. Yu earned her master's and bachelor's degrees in Engineering from Tsinghua University.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.